TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19076173
Drug: New classes
Approvals — FDA: no, EMA: no, PMDA: no
Description: New classes of oral anticoagulants (e.g., dabigatran, rivaroxiban)
Study: 15338504
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg qd
Study: 16960941
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg qd
Study: 12631041
Drug: i.v. propacetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. propacetamol 40 mg kg(‐1)
Study: 12631041
Drug: i.v. propacetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. propacetamol 20 mg kg(‐1)
Study: 12631041
Drug: i.v. propacetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. propacetamol 10 mg kg(‐1)
Study: 12631041
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (H, I, L)
Study: 11789281
Drug: Angelica sinensis
Normalized name: ANGELICA SINENSIS ROOT
DrugBank: Angelica sinensis root (DB14336)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angelica sinensis injection
Study: 11789281
Drug: 5% glucose
Normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glucose injection
Study: 7682581
Drug: Correlation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation with immunoglobulin G levels
Study: 2001826
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ranitidine at night
Study: 9412912
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ranitidine twice daily
Study: 26661319
Drug: Metoprolol CR/XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR/XL up-titrated to 200 mg/day
Study: 19608185
Drug: Probiotic strain
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic strain L. plantarum (DSM 9843)
Study: 15690537
Drug: Tac /
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tac / steroids
Study: 11871829
Drug: Methylprednisolone acetate
Normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone acetate (80 mg intramuscularly once weekly for 6 weeks)
Study: 11871829
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (40 mg/day in a 'tailing‐off' regimen)
Study: 9647268
Drug: Salmeterol 42
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 42 microg via metered-dose inhaler twice daily
Study: 11206232
Drug: Albuterol 180
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol 180 microg four times daily
Study: 2493023
Drug: Pyridostigmine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (120 mg, orally)
Study: 31192625
Drug: Experimental treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatments using logarithmic‐transformed ANOVA (LANOVA) and logarithmic‐transformed ANCOVA (LANCOVA)
Study: 28427388
Drug: Standard Speech
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Speech Therapy (SST) for 45 minutes, twice a week for 9 months
Study: 28427388
Drug: Movement, Cognition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Movement, Cognition and Narration of emotions treatment (MCNT) for 3 hours per day, 5 days a week for 9 months
Study: 28427388
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list for Standard Speech Therapy (SST) for 9 months
Study: 25256361
Drug: Dialogical exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialogical exposure group treatment using Gestalt empty‐chair method
Study: 25256361
Drug: Supportive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive group treatment
Study: 25256361
Drug: Dialogical exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialogical exposure group treatment
Study: 21439633
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (loading dose 1 g over 10 min followed by infusion of 1 g over 8 h)
Study: 12918131
Drug: Regimen 2
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen 2 (saccharomyces boulardii 250 mg Tid + metronidazole 750 mg Tid + iodoquinol 630 mg Tid for 10 days)
Study: 12918131
Drug: Regimen 1
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen 1 (metronidazole 750 mg Tid + iodoquinol 630 mg Tid for 10 days)
Study: 19659665
Drug: Allopurinol mouth
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol mouth rinse (1 mg/ml)
Study: 10604042
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract EGb 761 120 mg/d
Study: 10604042
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract EGb 761 240 mg/d
Study: 8770319
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg once daily for 6 weeks)
Study: 8770319
Drug: Pravastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (20 mg once daily for 6 weeks)
Study: 1682226
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg D,L-kawain
Study: 1682226
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg D,L-kawain
Study: 1682226
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg D,L-kawain
Study: 6958484
Drug: Budesonide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (100 micrograms daily)
Study: 30245281
Drug: Acetaminophen 975
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 975 mg
Study: 30245281
Drug: Ibuprofen 292.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 292.5 mg
Study: 25230866
Drug: 3-hour extended
Normalized name: alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-hour extended infusion of meropenem (1 g dissolved in 40 mL saline, followed by 750 mg continuous infusion for 3 hours, repeated every 8 hours)
Study: 25230866
Drug: 30-minute infusion
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-minute infusion of meropenem (1 g dissolved in 40 mL saline, intravenous infusion within 30 minutes every 8 hours)
Study: 25230866
Drug: 3-hour extended
Normalized name: alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-hour extended infusion of meropenem
Study: 25230866
Drug: 30-minute infusion
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-minute infusion of meropenem
Study: 20002472
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance tests (OGTT)
Study: 17480223
Drug: No mechanical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No mechanical bowel preparation (No-MBP)
Study: 14997083
Drug: Sufentanil (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (0.01 microg/kg/min) with propofol (site‐effect 3.0 microg/ml)
Study: 14997083
Drug: Remifentanil (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0.1 microg/kg/min) with propofol (site‐effect 3.0 microg/ml)
Study: 11642080
Drug: Diltiazem (120-180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (120-180 mg twice a day)
Study: 2480576
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) 1000 mg/kg
Study: 2480576
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) 750 mg/kg
Study: 25660106
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy with 5 methyl‐aminolevulinate
Study: 22968058
Drug: cutaneous lysate
Normalized name: Thermus thermophilus lysate
DrugBank: Thermus thermophilus lysate (DB11227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cutaneous lysate skin cream applied twice daily for 3 months
Study: 15871655
Drug: Cost-effective therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost-effective therapy
Study: 7890059
Drug: RU486 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU486 (50 mg daily for 6 months)
Study: 2098016
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with insect venom
Study: 28439893
Drug: Re-induction therapy
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-induction therapy (including fludarabine, cytarabine ± anthracyclines)
Study: 28439893
Drug: Allogeneic stem
Normalized name: Allogeneic human mesenchymal stem cell
DrugBank: Remestemcel-L (DB13973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic stem cell transplantation (SCT) as consolidation therapy after relapse
Study: 28439893
Drug: No SCT
Approvals — FDA: no, EMA: no, PMDA: no
Description: No SCT as part of relapse therapy
Study: 26022214
Drug: Partially defatted
Normalized name: rice bran, defatted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially defatted Granulated Brazil nut (GBN) 13 g per day (≈227.5 μg/day of selenium)
Study: 19404724
Drug: Telephone-administered cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered cognitive behavioral therapy (CBT)
Study: 15308881
Drug: Angiotensin‐converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin‐converting enzyme inhibitor therapy
Study: 15308881
Drug: Blood pressure
Normalized name: Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure treatment strategy achieving 128/78 mm Hg (low blood pressure goal)
Study: 10401453
Drug: Medication-free period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-free period (4 weeks)
Study: 7674179
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (no surface treatment)
Study: 7406949
Drug: Probucol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (4 X 250 mg per day for 4 months)
Study: 25132461
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide 3% topical gel
Study: 22782343
Drug: Huachansu plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huachansu plus gemcitabine (gemcitabine 1000 mg m(‐2) on days 1, 8, and 15 with huachansu 20 ml m(‐2) daily for 21 days)
Study: 22782343
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus gemcitabine (gemcitabine 1000 mg m(‐2) on days 1, 8, and 15 with placebo)
Study: 1973879
Drug: Phenoxybenzamine 140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenoxybenzamine 140 mg/day (Group I)
Study: 1973879
Drug: Phenoxybenzamine 270
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenoxybenzamine 270 mg/day (Group II)
Study: 6273551
Drug: Otosporin (antibiotic/steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otosporin (antibiotic/steroid ear drops)
Study: 27395330
Drug: Nutritional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional treatment + synbiotic (Lactobacillus and Bifidobacterium strains + 6 g fructooligosaccharides)
Study: 27395330
Drug: Nutritional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional treatment + placebo (6 g maltodextrin)
Study: 24862330
Drug: Aprepitant 125
Normalized name: aprepitant 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant 125 or 250 mg/d for 2 weeks
Study: 24862330
Drug: Aprepitant 375,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant 375, 625, 750, and 875 mg with exposure enhancement (EE)
Study: 24862330
Drug: Aprepitant doses
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant doses of 875 mg (625 mg with EE) or higher
Study: 19462434
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Calprotectin and Tumor M2-PK
Study: 16624765
Drug: 20% intralipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% intralipid (500 ml once a day) from postburn day 4 for 10 consecutive days
Study: 16624765
Drug: Non-intralipid treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-intralipid treatment (control group)
Study: 2005162
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (Control group, n=22)
Study: 6407293
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of sustained-release nitroglycerin (SRNG)
Study: 6407293
Drug: 6.5 mg
Normalized name: menthol 6.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.5 mg of sustained-release nitroglycerin (SRNG)
Study: 30520243
Drug: Exenatide monotherapy
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide monotherapy
Study: 28813878
Drug: Transcranial direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial direct current stimulation (tDCS) with wrist robot-assisted therapy
Study: 28813878
Drug: Sham stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham stimulation with wrist robot-assisted therapy
Study: 24339309
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 μg/kg followed by 0.1 μg/kg/h until the end of surgery
Study: 19173690
Drug: 10 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml/kg HES 130/0.42
Study: 19173690
Drug: 10 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml/kg gelatin
Study: 17502431
Drug: Indiplon (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indiplon (30, 50, and 80 mg)
Study: 15143450
Drug: Theophylline (5-7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (5-7 mg/kg body weight)
Study: 11435967
Drug: Basiliximab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basiliximab (20 mg i.v. on days 0 and 4)
Study: 9740480
Drug: valsartan 40
Normalized name: valsartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan 40 mg twice daily
Study: 21166600
Drug: valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan 80 mg twice daily
Study: 9740480
Drug: valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan 160 mg twice daily
Study: 9740480
Drug: lisinopril 5/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril 5/10 mg once daily
Study: 8047822
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily (weekend therapy)
Study: 8047822
Drug: Omeprazole 10
Normalized name: omeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 10 mg once daily (Italian study)
Study: 8047822
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily (weekend therapy, Italian study)
Study: 28656129
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (amoxicillin + clarithromycin + omeprazole)
Study: 28656129
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy plus Bifidobacterium lactis B94 (5 × 10^9 CFU/dose) plus inulin (900 mg) for 14 days
Study: 28656129
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy plus Bifidobacterium lactis B94 plus inulin
Study: 26076572
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic infiltration (7ml of local anesthetic: 4 ml of 0.25% bupivacaine and 3 ml of 2% lidocaine)
Study: 21426271
Drug: Bleaching with
Normalized name: Dioxybenzone/Hydroquinone/Padimate O 30 MG/1 GM-40 MG/1 GM-50 MG/1 GM Topical application Gel/Jelly [HYDROQUINONE SKIN BLEACHING WITH SUNSCREENS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleaching with White Smile, treatment with ascorbic acid and bonding with composite resin (G2)
Study: 21426271
Drug: Bleaching with
Normalized name: Dioxybenzone/Hydroquinone/Padimate O 30 MG/1 GM-40 MG/1 GM-50 MG/1 GM Topical application Gel/Jelly [HYDROQUINONE SKIN BLEACHING WITH SUNSCREENS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleaching with Opalesence, treatment with ascorbic acid and bonding with composite resin (G5)
Study: 19767078
Drug: C1 esterase
Normalized name: C1 esterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1 esterase inhibitor concentrate at a dose of 20 U/kg
Study: 19767078
Drug: C1 esterase
Normalized name: C1 esterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1 esterase inhibitor concentrate at a dose of 10 U/kg
Study: 12584828
Drug: Oxymatrine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymatrine 0.4 g/d by intramuscular injection for 3 months
Study: 12584828
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (liver protecting agents)
Study: 12584828
Drug: Oxymatrine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymatrine treatment
Study: 8521190
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment (0.1 IU/kg/day s.c.)
Study: 2156644
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of bendrofluazide plus inhaled salbutamol (1 mg doses)
Study: 2156644
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of bendrofluazide plus potassium, magnesium, or triamterene plus inhaled salbutamol (1 mg doses)
Study: 2156644
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of bendrofluazide plus 50 mg of triamterene plus inhaled salbutamol (1 mg doses)
Study: 2156644
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus inhaled salbutamol (1 mg doses)
Study: 6249334
Drug: Guanfacine 3
Normalized name: guanfacine 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine 3 mg
Study: 28682286
Drug: Oral diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diclofenac (50 mg, taken twice daily for 3 days)
Study: 28682286
Drug: Transdermal diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal diclofenac (100 mg, placed once daily for 3 days)
Study: 21554549
Drug: udenafil 200
Normalized name: udenafil
DrugBank: Udenafil (DB06267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: udenafil 200 mg
Study: 15521893
Drug: linezolid (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: linezolid (600 mg)
Study: 15521893
Drug: moclobemide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: moclobemide (300 mg)
Study: 2878942
Drug: Chlorpromazine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (30 mg)
Study: 28716796
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection then progressive exercise (≤6 sessions)
Study: 28716796
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection then best practice advice (one session)
Study: 26095263
Drug: Anti-VEGF injections
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-VEGF injections (control)
Study: 17199546
Drug: Flurbiprofen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (100 mg daily for 10 days) with scaling and root planing (SRP) in smokers (Group 3)
Study: 17199546
Drug: Flurbiprofen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (100 mg daily for 10 days) with scaling and root planing (SRP) in non-smokers (Group 1)
Study: 11287757
Drug: Acute oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute oral protein load in type 2 DM patients without microalbuminuria (MA)
Study: 11287757
Drug: Acute oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute oral protein load in healthy subjects
Study: 11287757
Drug: Acute oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute oral protein load in type 2 DM patients with microalbuminuria (MA)
Study: 8485790
Drug: Epidural anaesthesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural anaesthesia and analgesia (lidocaine 2% with epinephrine 1:200,000, 20 ml over 30 min; morphine 0.10 mg.kg‐1 after catheter insertion and 0.05 to 0.10 mg.kg‐1 every 12 hr as needed)
Study: 8485790
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia alone (nitrous oxide, oxygen, isoflurane, supplemented with intravenous fentanyl to a maximum of 10 micrograms.kg‐1)
Study: 3101606
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ACNU and Futraful (FT)
Study: 3101606
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ACNU and FT
Study: 3101606
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MMC and FT
Study: 3101606
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ADM and FT
Study: 1095794
Drug: Ibuprofen (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (800 to 1,600 mg daily)
Study: 1095794
Drug: Aspirin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (3 to 6 gm daily)
Study: 31219558
Drug: Transdermal testosterone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone, 300 μg daily for 24 weeks